Get the Stockscreener App
43.30
4.58%
-2.08
Ptc Therapeutics Inc stock is traded at $43.30, with a volume of 1.51M.
It is down -4.58% in the last 24 hours and down -10.81% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$45.38
Open:
$45.43
24h Volume:
1.51M
Relative Volume:
1.30
Market Cap:
$3.44B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-7.2896
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
-17.13%
1M Performance:
-10.81%
6M Performance:
-10.97%
1Y Performance:
+38.38%
1-Day Range:
$43.17
$46.43
1-Week Range:
$43.17
$52.45
52-Week Range:
$30.08
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
43.30 | 3.60B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
What is Leerink Partnrs' Estimate for PTCT FY2025 Earnings? - MarketBeat
Earnings Update: PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Momentum Screeners Rank PTC Therapeutics Inc. in Top 5 TodayCommunity Strategy With High Win Rate Backtested - metal.it
PTC Therapeutics (NASDAQ:PTCT) Shares Gap DownHere's Why - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $79.00 at Wells Fargo & Company - MarketBeat
PTC Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew B. Klein Sells 10,739 Shares - MarketBeat
PTC Therapeutics: Pioneering a New Growth Cycle in Rare Disease Innovation - AInvest
PTC Therapeutics and the Launch of Sephience™: A Catalyst-Driven Play in Rare Disease Innovation - AInvest
PTC Therapeutics Announces Q2 2025 Financial Results - The Globe and Mail
PTC Therapeutics outlines Sephience $1B-plus U.S. revenue potential following FDA and EU launches - MSN
Federated Hermes Inc. Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Beat Expectations But Shares Still Dropped - Finimize
PTC Therapeutics price target lowered to $70 from $72 at Baird - TipRanks
Transcript : PTC Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
PTC Therapeutics stock price target raised to $63 from $60 at RBC Capital - Investing.com Canada
PTC Therapeutics stock price target raised to $56 from $52 at TD Cowen - Investing.com Canada
RBC Raises Price Target on PTC Therapeutics to $63 From $60, Keeps Outperform Rating - MarketScreener
PTC Projects Confidence In Sephience Launch With Royalty Buyback - insights.citeline.com
Earnings call transcript: PTC Therapeutics beats Q2 2025 EPS expectations By Investing.com - Investing.com Nigeria
Morgan Stanley Raises Price Target on PTC Therapeutics to $76 From $70, Keeps Overweight Rating - MarketScreener
Ptc Therapeutics 2025 Q2 Earnings Strong Performance as Net Income Surges 34.6% - AInvest
PTC Therapeutics and Evolent Health Receive Bullish Sentiments from Analysts - AInvest
PTC Therapeutics: A Strategic Pivot to Sephience and the Path to Sustained Growth - AInvest
PTC Therapeutics Q2 Loss Narrows, Revenue Declines; Sets Full-Year Revenue Guidance - 富途牛牛
PTC Therapeutics Inc (PTCT) Q2 2025 Earnings Call Highlights: St - GuruFocus
PTC Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
PTC Therapeutics Reports Q2 2025 Financial Results - TipRanks
PTC Therapeutics Q2 2025 Earnings Preview - MSN
PTC Therapeutics: Balancing Optimism and Uncertainty Amidst New Product Launches and Regulatory Decisions - TipRanks
PTC Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PTC Therapeutics (PTCT): A Strategic Assessment of Growth Catalysts and Profitability Potential Post-Sephience Approval - AInvest
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Citizen Tribune
Uniqure N.V. shares rise 1.04% after-hours following PTC Therapeutics' positive Q2 earnings report. - AInvest
PTC Therapeutics: Q2 Earnings Snapshot - Stamford Advocate
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
PTC Therapeutics Enters Rights Satisfaction Agreement - TipRanks
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
PTC Therapeutics reports Q2 EPS (83c), consensus ($1.06) - TipRanks
PTC THERAPEUTICS Earnings Results: $PTCT Reports Quarterly Earnings - Quiver Quantitative
PTC Therapeutics Inc Surpasses Revenue Estimates with $179 Million in Q2 2025; Sephience Launch Marks Strategic Milestone - GuruFocus
PTC Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com Canada
PTC Therapeutics: Pioneering Rare Disease Innovation with a Diversified Pipeline and Strategic Growth Catalysts - AInvest
Press Release: PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - 富途牛牛
JPMorgan raises PTC Therapeutics stock price target to $68 on Sephience demand - Investing.com Canada
PTC Therapeutics: Strategic Shift and Robust Financials Drive Buy Rating with $68 Target by 2025 - TipRanks
PTC Therapeutics Earnings Preview: Analysts Expect $-1.07 EPS, Historical Performance and Stock Performance - AInvest
PTC Therapeutics Earnings Preview - 富途牛牛
Westfield Capital Management Co. LP Acquires New Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Inc. stock retracement – recovery analysisBuy Strategy Tracker with Growth Indicators - Newser
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):